Binnopharm Group Strengthens its Position in Southeast Asia by Commencing Registration of a Gastroenterology Drug in Vietnam

Leading Russian pharmaceutical company Binnopharm Group has applied for registration of a gastroenterology drug in the Vietnamese market.

Vietnam is a strategically important growth market for Binnopharm Group where gastrointestinal diseases are among the top 5 most common pathologies, affecting more than 27 million people and surpassing cardiovascular diseases in prevalence. Gastroenterology drugs form the largest category of the local pharmaceutical market, with a volume of over $1.4 billion. This creates a steady demand for modern therapeutic agents in this field.

Rustem Muratov, CEO of Binnopharm Group: «Filing an application in Vietnam is a logical next step in the implementation of Binnopharm Group’s international expansion strategy. We are consistently moving towards bringing our innovative drugs, which have proven their effectiveness and availability in Russia and the EAEU countries, to new markets. Following Vietnam, we are beginning to register drugs in other countries of the region, such as Indonesia and the Philippines».

The drug, which will be sold in Vietnam under the trade name Digebutin[1], is already registered not only in Russia, but also in Azerbaijan, Armenia, Belarus, Georgia, Kyrgyzstan, Moldova and Uzbekistan.

[1] Digebutin is a trimebutine-based drug, a gastrointestinal antispasmodic that normalises motility of the gastrointestinal tract (GIT). It is used to treat irritable bowel syndrome (IBS) and functional dyspepsia, effectively relieving the main symptoms: abdominal pain, spasms, bloating and discomfort.